65th ASH Annual Meeting & Exposition: 902. Health Services and Quality Improvement

Symposia: Health Services and Quality Improvement - Lymphoid Malignancies Oral and Poster Abstracts
Poster

Halls G-H (San Diego Convention Center)

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Patrick Squires, PharmD, PhD¹^*, Justin T. Puckett, BA²^*, Katherine Elizabeth Ryland, PhD³, Sachin Kamal-Bahl⁴^*, Monika Raut, PhD, MS³^*, Jalpa A. Doshi⁵^* and Scott F. Huntington, MD, MPH, MSc⁶

¹Merck & Co., Inc., North Wales, PA
²COVIA Health Solutions, Philadelphia, PA
³Merck & Co., Inc., Rahway, NJ
⁴COVIA Health Solutions, Lansdale, PA
⁵University of Pennsylvania, Philadelphia, PA
⁶Division of Hematology, Yale University, New Haven, CT

2327

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP

Dong Won Baek, MD, PhD¹^*, Ga-Young Song²^*, Hyukjin Choi³^*, Ho Sup Lee, MD⁴^*, Young Rok Do, PhD, MD⁵, Ji Hyun Lee, MD, PhD⁶, Joon Ho Moon, MD⁷ and Deok-Hwan Yang⁸^*

¹Department of Hematology, Kyungpook National University Hospital, Daegu, South Korea
²Chonnam National University Hwasun Hospital, Hwasun, KOR
³Kyungpook National University Hospital, Daegu, Korea, Republic of (South)
⁴Kosin University Gospel Hospital, Busan, Korea, Republic of (South)
⁵Dongsan Medical Center, Keimyung University, Daegu, Korea, Republic of (South)
⁶Dong-A University College of Medicine, Busan, South Korea
⁷Department of Hematology-Oncology, Kyungpook National University Hospital, Seoul, Korea, Republic of (South)
⁸Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)

2328

Toward AI-Assisted Clinical Assessment for Patients with Multiple Myeloma: Feature Selection for Large Language Models

Ehsan Malek, MD¹, Gi-Ming Wang²^*, Anant Madabhushi¹^*, Jennifer Cullen¹^*, Curtis Tatsuoka³^* and James J. Driscoll II, MD, PhD⁴

¹Case Western Reserve University, Cleveland, OH
²Case Western Reserve University, Cleveland
³University of Pittsburg, Pittsburg
⁴University Hospitals Seidman Cancer Center, Cleveland, OH

2329

Incidence of Infections Associated with the Use of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas

Amneh A Fares, PharmD¹^*, Diana Martinez, PharmD¹^*, Saba Musleh Ud Din, MD²^*, Robert Wilkinson, PharmD¹^*, Julio C Chavez, MD³, Fernando Manuel Vargas Madueno, MD⁴ and Jose Sandoval-Sus, MD⁴

¹Department of Pharmacy, Memorial Healthcare System, Pembroke Pines, FL
²Department of Internal Medicine, Memorial Healthcare System, Pembroke Pines, FL
³Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁴Department of Malignant Hematology and Cellular Therapy, Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL

2330

The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US)

Farrukh T. Awan, MD¹, Aleksandra Vidisheva²^*, Matia Saeedian²^*, Murat Kurt³^*, Simran K. Tiwana³^* and Masoom Priyadarshini³^*

¹University of Texas Southwestern Medical Center, Dallas
²BluePath Solutions, Los Angeles, CA
³Bristol Myers Squibb, Princeton, NJ

2331

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Monica Rondi¹^*, Silvia Ferrari¹^*, Anna Maria Barbui, MD¹^*, Andrea Rossi, MD¹^*, Chiara Pavoni¹^*, Anna Grassi¹^*, Federico Lussana, MD, PhD^2,3^*, Alessandro Rambaldi, M.D.^4,5 and Giuseppe Gritti¹^*

¹Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
²Department of Oncology-Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
³Department of Oncology and Hematology, University of Milan, Milan, Italy
⁴Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo BG, Italy
⁵Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

2332

Approval Delay in Drugs from Non-Global Company in Europe and Japan: Analysis of Novel Drugs for Hematologic Malignancies

Kensuke Matsuda, MD, PhD¹^*, Sumimasa Nagai, MD, PhD² and Koichi Sugimoto³^*

¹Office of New Drug Ⅴ, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
²Kyoto University, Kyoto, JPN
³JR Tokyo General Hospital, Tokyo, JPN

2333

Medical Insurance Coverage and Clinical Outcomes for Patients with Hematological Malignancies in a Rural State

Kingsley Chinonyerem Nnawuba, MD¹, Samantha Robinson²^*, Suzette Lopez³^*, Mohammod Rahman⁴^* and Hanna Jensen, MD, PhD.³^*

¹Internal Medicine, University of Arkansas for Medical Sciences, Rogers, AR
²University of Arkansas, Fayetteville, AR
³University of Arkansas for Medical Sciences, Fayetteville, AR
⁴University of Kansas Medical Center, Kansas City, KS

2334

Treatment Outcome Priorities of Older Adults with Newly Diagnosed Blood Cancers Elicited with Best-Worst Scaling

Daniel R. Richardson, MD, MSc, MA¹, Carl J. Mhina²^*, Matthew Washko³^*, Allison M Deal, MS⁴^*, Amy C. Cole¹^*, Mattias Jonsson⁴^*, Stephanie B Wheeler¹^*, Norah L Crossnohere, PhD⁵^* and John F.P. Bridges⁵^*

¹University of North Carolina, Chapel Hill, NC
²Duke University, Durham, NC
³University of North Carolina at Chapel Hill, Chapel Hill, NC
⁴Lineberger Comprehensive Cancer Center, Chapel Hill, NC
⁵The Ohio State University, Columbus, OH

2335

Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service

John L Vaughn, MD, MS¹, Man-Yee Merl, PharmD, BCOP²^*, Jensa C Morris, MD¹^* and Bonnie E Gould Rothberg, MD, PhD, MPH, MMM¹^*

¹Smilow Hospitalist Service, Yale New Haven Hospital, New Haven, CT
²Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, CT

2336

Economic Burden Associated with ASCT in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nationwide Health Insurance Claims Database Study in Japan during 2012-2022

Saaya Tsutsué, PhD¹, Shinichi Makita, MD, FACP, PhD²^*, Hiroya Asou, MD, PhD³, Shingo Wada, MS⁴^*, Wen Shi Lee, MBBS, PhD⁴^*, Dili Ainiwaer, PhD⁴^*, Koki Idehara, PhD⁴^*, Sona-Sanae Aoyagi, PhD⁴^* and Seok-Won Kim, PhD⁴^*

¹Kite Value and Access, Gilead Sciences Japan, Tokyo, Japan
²National Cancer Center Hospital, Tokyo, Japan
³Kite Clinical Development, Gilead Sciences Japan, Tokyo, Japan
⁴IQVIA Solution Japan, Tokyo, Japan

2337

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Asher Alban Chanan-Khan, MD¹, Kirollos S. Hanna²^*, Mei Xue, MBA³^*, Marjan Massoudi, PharmD³^*, Mark Balk, PharmD³^*, Hossein ZivariPiran, PhD⁴^*, Cecilia Duan⁵^* and Keri Yang, PhD, MBA, MPH, MS, CPM, BSPharm³^*

¹Mayo Clinic Florida, Jacksonville, FL
²Minnesota Oncology, St. Paul, MN
³BeiGene USA, Inc, San Mateo, CA
⁴Evidera, Montreal, QC, Canada
⁵Evidera, London, United Kingdom

2338

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD¹, Ashley Bonner²^*, Pearl Wang²^*, Lamees Almuallem²^*, Jigar Desai³^*, Omotayo Fasan³, Thalia Farazi⁴, Jinender Kumar³^* and Saurabh Dahiya^5,6^*

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²EVERSANA, Burlington, ON, Canada
³Bristol Myers Squibb, Princeton, NJ
⁴Bristol Myers Squibb, San Francisco, CA
⁵Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Palo Alto, CA
⁶University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, MD

2339

MRD Assessment in Patients with Newly Diagnosed Multiple Myeloma Using Tokenized Real World Data Sources

Miao Jiang, PhD, MS¹^*, Anthony Hewitt¹^*, Jorge Zuloaga, PhD²^*, Aaron Neiderhiser²^*, Thu Xuan Vu²^* and Heidi Simmons, PhD³

¹Adaptive Biotechnologies, Seattle, WA
²Tuva Health, Salt Lake City
³Adaptive Biotechnologies Corporation, Seattle, WA

2340

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey¹^*, Matthew Gitlin¹^*, Abraham Lee¹^*, Scott J. Keating²^*, Victoria Barghout³^* and Simran K. Tiwana²^*

¹BluePath Solutions, Los Angeles, CA
²Bristol Myers Squibb, Princeton, NJ
³VEB HealthCare LLC, Morristown, NJ

2341

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Reid M. Muenzen, MD¹, Emeline R. Chong²^*, Dylan Therwhanger, MD²^*, Daniel J. Landsburg, MD², Sunita D. Nasta, MD², Jakub Svoboda, MD², Stefan K. Barta, MD², Mitchell E. Hughes, PharmD²^*, Elizabeth Weber³^*, Marco Ruella, MD², Noelle V. Frey, MD, MS⁴, David L. Porter, MD⁴, Stephen J. Schuster, MD² and Elise A. Chong, MD²

¹Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
²Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
³Cell Therapy and Transplant, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁴Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

2342

Development of a Clinical Trial Methodology and Appraisal Curriculum for Hematology Fellows

Matthew James Brunner, MD

Department of Medicine Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI

2343

Safety and Financial Analysis of Outpatient Hypercvad Arm a Administration for Acute Lymphoblastic Leukemia

Yujiao Sun, PharmD^1,2^*, Ariel Denson, PharmD¹^*, Katherine Tobon, PharmD¹^*, Rebecca Jean Nelson, PharmD¹^*, Amber Lubas, MMSc, MPH, PA-C³^*, Bijal D. Shah, MD³, Timothy Kubal, MD, MBA³, Christopher Rodriguez Salamanca, PA-C³^*, Jad Chahoud, MD, MPH⁴^*, Javier Pinilla-Ibarz, MD, PhD³ and Leidy Lismeris Isenalumhe, MD, MS⁵

¹Department of Pharmacy, Moffitt Cancer Center, Tampa, FL
²Ronald Reagan UCLA Medical Center, Los Angeles, CA
³Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁴Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL
⁵Moffitt Cancer Center, Tampa, FL

2344

The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Aroog Khaliq¹^*, William Wesson, MPH², Emerson Logan²^*, Carine Tabak²^*, Aliya Rashid, DO, MPH², Razan Mansour³^*, Muhammad Umair Mushtaq, MD^4,5, Joseph P McGuirk, DO⁴, Hamza Hashmi, MD^5,6^*, Mehdi Hamadani, MD⁷, Al-Ola Abdallah, MD^5,8 and Nausheen Ahmed, MD^5,8,9

¹University of Kansas School of Medicine, Overland Park, KS
²University of Kansas School of Medicine, Kansas City, KS
³Internal Medicine, University of Kansas Medical Center, Kansas City, KS
⁴University of Kansas Medical Center, Westwood, KS
⁵US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
⁶Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
⁷Division of Hematology and Oncology, The Medical College of Wisconsin Inc, Milwaukee, WI
⁸Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
⁹The University of Kansas Cancer Center, Westwood, KS

2345

Universal and Equitable Access to High-Cost Drugs in Uruguay. Results of 15 Years of Treatment of Non-Hodgkin Difusse Large B Cell Lymphoma (DLBCL) with Ritiximab in First Line Treatment in Uruguay

Carolina Majo, MD^*, Natalia Piñeiro, MD^*, Jimena Janssen, MD^*, Pablo Muxi, MD and Abayubá Perna, MD^*

Fondo Nacional de Recursos, Montevideo, Uruguay

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.P1.57 902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I